Samjin Pharmaceutical Partners with Arontier for AI-Based Immuno-Oncology Drug Development

Samjin Pharmaceutical announced on the 25th that it has signed a contract with AronTier, a domestic artificial intelligence (AI) new drug development platform company, for joint research on AI-based immune oncology drug development.

Sumin Lee, Head of Research Center at Samjin Pharmaceutical (left), and Junsu Ko, CEO of Arontier, are posing for a commemorative photo at the joint research contract signing ceremony.
[Photo by Samjin Pharmaceutical]

Through this agreement, Samjin Pharmaceutical will propose drug targets to AronTier, and AronTier plans to quickly secure candidate substances with high development potential by applying its innovative new drug development platform AD3 technology. Subsequently, Samjin Pharmaceutical will verify and optimize the candidate substances discovered by AronTier and proceed with the necessary procedures for commercialization. The intellectual property rights for the derived new drug candidates will be jointly owned by both companies, with Samjin Pharmaceutical holding exclusive rights necessary for commercialization.

Lee Soo-min, Head of Research Center at Samjin Pharmaceutical, said, “Samjin Pharmaceutical and AronTier were respectively selected as the lead research institutions for the AI-utilized innovative new drug discovery project promoted by the Ministry of Science and ICT last year and this year, and are currently actively leading related projects. Through this agreement, we will strive to develop next-generation immune oncology drugs that overcome unmet needs in the market by utilizing the advanced technologies of both companies and contribute to creating an AI-based innovative new drug development ecosystem.” AronTier CEO Ko Joon-soo said, “We are pleased that AronTier’s AI innovative new drug development platform can contribute to Samjin Pharmaceutical’s immune oncology drug development through this contract. Through the cooperation of both companies, we will work to develop innovative immune oncology drugs and provide new treatment options for patients with intractable cancers.”

AronTier, established in 2017, is an innovative new drug development startup based on AI-utilized protein structure, conducting numerous government projects and joint research for innovative new drug development with Samsung Medical Center, Daegu-Gyeongbuk Medical Innovation Foundation, and others.

This content was produced with the assistance of AI translation services.